<DOC>
	<DOC>NCT00319787</DOC>
	<brief_summary>The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate specific antigen (PSA) levels.</brief_summary>
	<brief_title>Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>18 to 80 years of age. Men with histologically confirmed locally advanced prostatic adenocarcinoma No prior treatment for prostate cancer, including surgery, radiotherapy, cryotherapy or thermotherapy. No abnormal laboratory values. No coexisting malignancies and any other significant clinical disorder or laboratory finding.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>